Navigation Links
CV Therapeutics Reports 2007 Third Quarter Financial Results
Date:11/6/2007

nd go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6247, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Tuesday, November 13, 2007. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 20300373.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statemen
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... emissions will reduce other harmful air pollution and ... new study released today. The research shows that, ... final Clean Power Plan, the power plant standards ... and hundreds of heart attacks in the United ... Co-benefits of Carbon Standards for Existing Power Plants, ...
(Date:9/30/2014)... R.I. [Brown University] Autism is no stranger to ... East African nation is access to clinical services, including ... diagnostic measure, for example, validated for use in Swahili, ... new study, however, researchers at Brown University and the ... approach that they implemented at two sites in the ...
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth ... new medical specialty practice through a unique partnership with ... be located within the company’s Shrewsbury location and will ... Tawfik of American Heart Center, P.C., a highly regarded ... offer Integrated Medicine Alliance patients top notch cardiovascular care ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 ... Blue Star Nutraceuticals designed to help maximize lean, strong ... optimizes the body’s absorption of glucose has caught the ... , “The main purpose behind Glycodrive is to help ... lean muscle,” reports Michaels. “Carbs are essential in the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 VisitandCare.com ... in Turkey has gone up more than 79 percent ... medical tourism company also reported total revenue tripled for ... , The company’s professional strategy has allowed them to ... ultimately designed for patient comfort and privacy — with ...
Breaking Medicine News(10 mins):Health News:Power plant standards could save thousands of US lives every year 2Health News:Power plant standards could save thousands of US lives every year 3Health News:New diagnostic approach for autism in Tanzania 2Health News:New diagnostic approach for autism in Tanzania 3Health News:New diagnostic approach for autism in Tanzania 4Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4
... available through Lifeboat,s reseller network; Services seen as complement to ... ... Northglenn, CO (PRWEB) March 5, 2009 -- ImageDoc USA, ... a distribution agreement with Lifeboat Distribution, an international specialty software ...
... patients with better results, lower cost, less discomfort, faster recovery ... ... Boca Raton, FL (PRWEB) March 5, 2009 -- A new ... improve hair transplant surgery for male and female patients., , ...
... and resources for patients and their families , ... ... brain injuries each year through falls, traffic accidents, sports and other ... (BIAA), which is observing National Brain Injury Awareness Month in March ...
... evaluate the effectiveness of current continuing medical education ... recommendations on how those practices need to change ... of CHEST , the peer-reviewed journal of ... of Continuing Medical Education: American College of Chest ...
... also been accepted for publication as an original article ... 4 NewCardio, Inc. (OTC Bulletin Board: NWCI) a ... Ihor Gussak, NewCardio,s Vice President and Chief Medical Officer, ... 58th Annual Scientific Session in Orlando on March 29, ...
... The following is a statement by Matthew ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The House Energy and Commerce Committee today ... historic action to reduce tobacco use by approving ... authority over tobacco products. Today,s 39-13 vote ...
Cached Medicine News:Health News:Lifeboat Distribution and ImageDoc USA Sign Distribution Agreement 2Health News:New NeoGraft™ Device Improves Hair Transplants 2Health News:New NeoGraft™ Device Improves Hair Transplants 3Health News:Nearly 1.4 Million Sustain Traumatic Brain Injuries Each Year 2Health News:New CME guidelines advise paradigm shift in physician education 2Health News:New CME guidelines advise paradigm shift in physician education 3Health News:UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting 2Health News:UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting 3Health News:UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting 4Health News:House Committee Vote Sets Congress on Course for Historic Regulation of Tobacco Products 2Health News:House Committee Vote Sets Congress on Course for Historic Regulation of Tobacco Products 3
(Date:9/30/2014)...   Decision Resources Group finds that through ... kidney disease non-dialysis (CKD-ND) patients are not highly ... addition, one-year persistency is similar between Amgen,s Aranesp ... findings from the report entitled Treatment ... Agents in Late Stage Chronic Kidney Disease and ...
(Date:9/30/2014)... MUNSTER, Ind. , Sept. 30, 2014  The orthopedic ... ranked the nation,s No. 6 orthopedic group by US ... for Active Adults," a series of free, public seminars ... from all over the world come to see the ... replacement procedures are now available at Munster Specialty Surgery ...
(Date:9/30/2014)... In 2011, approximately 5.1 million people in ... pain relievers (e.g. opioids). 1 Clinical treatments for ... the use of buprenorphine, buprenorphine/naloxone, naltrexone or methadone. The ... developing and improving care management programs, according to ... Therapeutics LLC (Prime). Cost trends ...
Breaking Medicine Technology:Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Inquire...
Medicine Products: